MC4R and Bardet-Biedl syndrome: There is currently only one approved pharmaceutical intervention for BBS, which is indicated for just one non-universal feature of the syndrome – Imcivree (setmelanotide), a melanocortin 4 receptor (MC4R) agonist, has been approved for treatment of hyperphagia in the US and UK (Markham, 2021).